Webinars
Join Anastasiya Smith, Snr. Director of R&D at Marker Therapeutics for a 15-minute pre-recorded webinar covering the first critical steps in successful automation through simplification with the G-Rex® platform.
Literature
ScaleReady sets out a staged partnership model for moving T cell and NK cell therapy programmes from discovery through to commercial manufacture, and reports no experiments, patients or laboratory measurements. The stages named are discovery, product testing, proof of concept, custom protocols, data review, process optimisation, process scaling, scalable results and commercialisation. The company states that testing done at minimum scale is fully translational to maximum scale, and that repeatability, consistency and predictability of outcomes are preserved without sacrificing quality or cost. Technical account managers and field application specialists arrange samples and in-person demon…
Literature
T-Cells
Moving from research-grade to animal-free GMP-grade recombinant human IL-2 left T cell growth, viability and memory phenotype essentially unchanged. In the supporting comparison, peripheral blood mononuclear cells from three donors were processed on a Fresenius Kabi Lovo automated cell processing system, CD4+ and CD8+ T cells were positively selected, and each grade of IL-2 was tested at 200 IU/mL in a Wilson Wolf G-Rex® 6M well plate for three days, followed by 10 to 11 further days with fresh medium and IL-2. Fold expansion, viability, CD62L and CCR7 positivity and the split between Tscm/Tcm and Teff/Tem subsets were comparable across grades. The GMP protein carries the same cysteine to…
Literature
T-Cells
Three separate lots of new GMP-grade recombinant human IL-7 and IL-15 gave comparable total cell numbers and viability when CD4+ and CD8+ T cells from one human donor were cultured for 14 days and read by flow cytometry on day 14. Bioactivity was consistent lot to lot across three manufacturing runs, measured on the CTLL-2 mouse cytotoxic T-cell line for IL-2, on PHA-activated human peripheral blood lymphocytes for IL-7, and on the MO7e human megakaryocytic leukaemia line for IL-15. Protein from the new animal-free facility in St Paul, Minnesota matched the original GMP lots with ED50 values inside the margin of error, and the new IL-2 carries the cysteine-to-serine substitution found in…
Literature
T-Cells
Two lots of GMP recombinant human IL-7 made in a new dedicated animal-free facility in St Paul, Minnesota matched the legacy GMP IL-7 product, giving ED50 values within the margin of error in a proliferation bioassay on PHA-activated human peripheral blood lymphocytes. Both share the Asp26-His177 sequence with an N-terminal methionine from accession P13232, are expressed in E. coli, exceed 97 per cent purity and give a dominant mass spectrometry peak at 17518. Host cell protein sits below 0.5 ng/ug by ELISA, endotoxin below 0.01 by LAL method, mycoplasma is negative and sterility follows USP71. The new material is lyophilised in PBS with trehalose and supplied in 25 and 1000 ug packs.
Case Studies
T-Cells
G-Rex®500M-CS
Seeding density, not vessel format, set the ceiling on T cell yield when an autologous T cell therapy company moved its expansion step into closed-system bioreactors. Working with ScaleReady, the company first confirmed that a G-Rex®500M-CS protocol started at a calculated seeding density in cells/cm2 matched the expansion rate and target cell characteristics of its existing open process, clearing the way for pivotal trials. Small-scale G-Rex®6M well plate runs then showed that starting density directly changes fold expansion and final yield, identifying a better density along with a reduced media and cytokine feeding schedule. Because the well plates and the 500M-CS gave similar kinetics…
Case Studies
TCR T Cells
G-Rex®500M-CS
A manufacturing cost model built around G-Rex® 500M-CS bioreactors showed that up to 2,500 patients a year could be processed within a 500 square foot cell therapy suite. ScaleReady produced the forecast for a company developing autologous TCR T cell therapies whose process development group had already confirmed that G-Rex® expansion and phenotype met their quality requirements at small and large scale. Because G-Rex® production scales linearly, vessel consumption was projected from the target cells per patient dose, the number of vessels per dose, manufacturing time and expected patient numbers through trials into commercial supply. The model priced hardware, consumables, manufacturing…
Case Studies
T-Cells
A company developing autologous T cell therapies for solid tumours completed the switch from research-grade to GMP-grade cytokines after generating data showing comparable bioactivity and consistent lot-to-lot performance across three lots of each GMP cytokine. ScaleReady supplied certificates of analysis, stability data and bioactivity documentation for specification comparison, and the company confirmed that the GMP and research-grade proteins use the same clone and manufacturing process. On waste, 2 of the 3 GMP cytokines were already sold off-the-shelf in smaller vials meeting the minimum activity per vial the process needed, and custom activity-per-vial filling is being pursued for t…
Literature
CAR T Cells, NK Cells, T-Cells
G-Rex®100M, G-Rex®500M
Application data in this G-Rex® brochure show gene-edited T cells scaling across vessel sizes without changing the protocol: 1 x 10^7, 8 x 10^7 and 40 x 10^7 T cells electroporated with TcBuster were transposed at above 30 per cent efficiency and expanded 25-, 50- and 38-fold in G-Rex®6M, G-Rex®100M and G-Rex®500M, giving yields of 2.5 x 10^8, 4 x 10^9 and 15 x 10^9 cells. Purified CD3+ T cells seeded at 0.5 x 10^6 per well in G-Rex®6M with ExCellerate medium, GMP IL-7, GMP IL-15 and Cloudz expanded through day 10. Human NK cells seeded at 3 x 10^4 cells/cm^2 expanded roughly 300-fold in 10 days, and a single cytokine dose at day 0 matched repeated feeding.
Videos
In this recorded symposium, cell therapy manufacturing leaders speak about defining and planning for intelligent commercial scale up and scale out. Recorded at ISCT 2021.
Literature
CAR T Cells, NK Cells, T-Cells
G-Rex®100M, G-Rex®500M
Cells edited with the TcBuster transposon system expanded 25-, 50- and 38-fold in small, mid- and large-scale G-Rex® vessels while holding transposition above 30 per cent at every scale. Inputs of 1 x 10^7, 8 x 10^7 and 40 x 10^7 electroporated cells were seeded into G-Rex®6M, G-Rex®100M and G-Rex®500M respectively and returned 2.5 x 10^8, 4 x 10^9 and 15 x 10^9 cells, with measured transposition of 40, 51.3 and 40.9 per cent. Flow cytometry put CAR expression after transposition at 59.2 per cent against 51.1 per cent for lentivirus. The non-viral system carries cargo over 11 kb and multiple genes at once.
Literature
NK Cells, T-Cells
ExCellerate NK Cell Expansion Media outgrew two rival commercial NK formulations over a 14-day culture and finished at 85.3 per cent purity for CD3-negative, CD56-positive cells. That fraction climbed from 6.0 per cent on day 0 to 49.5 per cent by day 7 and 65.0 per cent by day 9. These NK cultures began as PBMCs from three human donors and were driven by IL-2, IL-12, IL-18 and IL-21. A parallel run on the T cell side placed purified CD3-positive human T cells at 0.5 x 10^6 per well in G-Rex®6M vessels, using ExCellerate T Cell Expansion Medium supplemented with GMP-grade IL-7 and IL-15; fold expansion and viable yield were read on days 3, 6, 8 and 10.
No manuscripts match your filters.